You are here: Industry Insights > PD-L1

News List

AstraZeneca's head and neck cancer treatment Imfinzi falls flat in Phase III trials pharmafile
December 10, 2018
AstraZeneca’s immunotherapy treatment Imfinzi has failed to meet its primary goal in treating head and neck cancer in the Phase III EAGLE trial.
Roche pulls extended use application for kidney cancer drug pharmaphorum
November 26, 2018
Roche has withdrawn an application to the European Medicines Agency (EMA) for an expanded use for its immunotherapy drug, Tecentriq....
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin (bevacizumab) as a first-line treatment for renal cell carcinoma (RCC) due to insufficient
AstraZeneca gets back to growth, but can it hit $40B by 2023? CEO says yes—again fiercepharma
November 11, 2018
AstraZeneca CEO Pascal Soriot has repeatedly said his company would finally get back on the upswing in the second half of this year, and he’s put skeptics to rest with strong third-quarter numbers. Now, he’s doubling down on an even more ambitious promise
Shuwen Biotech gets PD-L1 Detection Kit validation in Clinical Trials biospectrumasia
September 18, 2018
Patients with advanced esophageal squamous cell carcinoma with higher PD-L1 expression can benefit better from leading PD-1 antibody drugs
And Platinum Pharmaceuticals and Columbotech Global Strategic Cooperation on PD-L1 Antibody A167 pharmafocusasia
August 21, 2018
With Plasma BioMed and Sichuan Kelun Botai Biomedical Co., Ltd. focusing on innovative drug development (" Columbotech" announced the global strategic cooperation......
China’s Harbour BioMed, Kelun ink a PD-L1 deal worth up to $350M fiercebiotech
August 21, 2018
Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China. Kelun stands to earn up to $350 million, but the partners did not specify how much the deal was worth upfront.
Keytruda extends survival in first-line head and neck cancer trial pharmatimes
July 26, 2018
MSD’s Keytruda significantly extended overall survival when used as monotherapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients expressing PD-L1.
Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research b3cnewswire
July 04, 2018
Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.

Previous page 1 2 3 4 5 Next page